Shots:

• Study 2 of the P-III SELECT-AXIS 2 clinical trial evaluates the efficacy & safety of upadacitinib (qd- 15mg) vs PBO in 314 adults with active nr-axSpA
• The trial met its 1EPs of ASAS40 response & 2EPs @14wks.- patients achieved ASAS40 response & ASDAS low disease activity (45% vs 23%) & (42% vs 18%)- reductions in signs & symptoms including back pain & inflammation- improvements in physical function (-2.61 vs -1.47) @14wks.
• Additionally- improvement in MRI SPARCC score (-2.49 vs 0.57); mean change from baseline in patient's assessment of total back pain (-2.91 vs -2.00)- safety data were consistent with previous studies & known safety profile of the therapy- no new risks were observed

  | Ref: AbbVie | Image:abbvie